Cochrane · systematic review · CD011088
Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism
Robertson, L, Yeoh, SE, Ramli, A · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
VascularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
10
No studies
4
Included studies
NR
No studies 4 · 28.6%Ungraded 0 · 0%Very low 0 · 0%Low 5 · 35.7%Moderate 5 · 35.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Extended prophylaxis compared to placebo in patients with unprovoked venous thromboembolism
Population: patients with unprovoked venous thromboembolism
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
VTE‐related mortalitya Extended prophylaxis vs placebo | OR 0.98 [0.14, 6.98] | 4 studies · 1862 participants | Low Downgraded: risk of bias, imprecision |
Recurrent VTEc Extended prophylaxis vs placebo | OR 0.63 [0.38, 1.03] | 5 studies · 2043 participants | Moderate Downgraded: risk of bias, imprecision |
Major bleedinge Extended prophylaxis vs placebo | OR 1.84 [0.87, 3.85] | 5 studies · 2043 participants | Low Downgraded: risk of bias, imprecision |
All‐cause mortalityg Extended prophylaxis vs placebo | OR 1 [0.63, 1.57] | 5 studies · 2043 participants | Moderate Downgraded: risk of bias, imprecision |
Clinically relevant non‐major bleedingh Extended prophylaxis vs placebo | OR 1.78 [0.59, 5.33] | 4 studies · 1672 participants | Low Downgraded: risk of bias, imprecision |
Strokei Extended prophylaxis vs placebo | OR 1.15 [0.39, 3.46] | 2 studies · 1224 participants | Low Downgraded: risk of bias, imprecision |
Myocardial infarction Extended prophylaxis vs placebo | OR 1 [0.35, 2.87] | 3 studies · 1495 participants | Low Downgraded: risk of bias, imprecision |
VTE extended prophylaxis compared to another VTE extended prophylaxis in patients with unprovoked venous thromboembolism
Population: patients with unprovoked venous thromboembolism
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
VTE‐related mortalitya VTE extended prophylaxis vs another VTE extended prophylaxis | no estimate extracted | NR | No studies |
Recurrent VTEb VTE extended prophylaxis vs another VTE extended prophylaxis | OR 0.28 [0.15, 0.54] | 1 study · 1389 participants | Moderate Downgraded: imprecision |
Major bleedingd VTE extended prophylaxis vs another VTE extended prophylaxis | OR 3.06 [0.37, 25.51] | 1 study · 1389 participants | Moderate Downgraded: imprecision |
All‐cause mortalitye VTE extended prophylaxis vs another VTE extended prophylaxis | no estimate extracted | NR | No studies |
Clinically relevant non‐major bleedingf VTE extended prophylaxis vs another VTE extended prophylaxis | OR 0.84 [0.37, 1.94] | 1 study · 1389 participants | Moderate Downgraded: imprecision |
Strokeg VTE extended prophylaxis vs another VTE extended prophylaxis | no estimate extracted | NR | No studies |
Myocardial infarction VTE extended prophylaxis vs another VTE extended prophylaxis | no estimate extracted | NR | No studies |